Kenneth Truitt

Aquestive Therapeutics, Inc. (AQST)

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Kenneth Truitt

Aquestive Therapeutics, Inc. reported in an 8-K filed August 10, 2022 that Kenneth Truitt was appointed Chief Medical Officer, effective September 6, 2022.

“announced today the appointments of Timothy E. Morris to the Company's Board of Directors, effective August 5, 2022, and Kenneth Truitt, M.D., as Chief Medical Officer effective September 6, 2022.”

Aquestive Therapeutics, Inc. Form 8-K, filed August 10, 2022 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Research with Equibles

Turn this profile into a cited research brief

Start with a question tailored to the filings and events on this page, or connect Equibles financial data to ChatGPT or Claude.

Suggested question: “Summarize Kenneth Truitt's recent executive appointments or departures and cite the source filings.”

Use in your AI

Affiliation history

Recorded current and former roles; source labels appear when available.

Aquestive Therapeutics, Inc. (AQST)
SEC 8-K

Current
2022-09-06–present

Company network

Recorded roles and call appearances connecting this person to public companies.

Aquestive Therapeutics, Inc.

AQST

Current role

Leadership on record at Aquestive Therapeutics, Inc.

Other people whose current roles at this company are on record from its filings.

Daniel Barber CEO, Board Member
Gregory B. Brown Chairman
John S. Cochran Chairman
A. Ernest Toth CFO
A. Ernest Toth, Jr. CFO
Cassie Jung COO
Thomas A. Zalewski General Counsel
Abigail L. Jenkins Board Member
Julie Krop Board Member
Marco Taglietti Board Member

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.

Executive change Appointed: Chief Medical Officer Aquestive Therapeutics, Inc. (AQST)
2022-09-06